Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)

Duvelisib, an oral dual inhibitor of PI3K-δ and PI3K-γ, is in phase III trials for the treatment of chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin’s lymphoma (iNHL). In CLL, duvelisib monotherapy is associated with high iwCLL and nodal response rates, but complete remissions are rare. T...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Leukemia
Egile Nagusiak: Patel, Viralkumar M., Balakrishnan, Kumudha, Douglas, Mark, Tibbitts, Thomas, Xu, Ethan Y., Kutok, Jeffery L., Ayers, Mary, Sarkar, Aloke, Guerrieri, Renato, Wierda, William G., O’Brien, Susan, Jain, Nitin, Stern, Howard M., Gandhi, Varsha
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5540815/
https://ncbi.nlm.nih.gov/pubmed/28017967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.382
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak